AWH Stock - Aspira Women's Health Inc.
Unlock GoAI Insights for AWH
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $9.18M | $9.15M | $8.18M | $6.81M | $4.65M |
| Gross Profit | $5.48M | $5.26M | $4.32M | $3.06M | $1.24M |
| Gross Margin | 59.7% | 57.5% | 52.8% | 45.0% | 26.6% |
| Operating Income | $-16,278,000 | $-18,852,000 | $-31,138,000 | $-32,595,000 | $-17,981,000 |
| Net Income | $-13,094,000 | $-16,690,000 | $-29,885,000 | $-31,710,000 | $-17,905,000 |
| Net Margin | -142.6% | -182.3% | -365.2% | -465.5% | -385.0% |
| EPS | $-0.93 | $-1.81 | $-3.85 | $-4.28 | $-2.67 |
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company provides OVA1, OVERA, and OVA1plus to detect risk of ovarian malignancy in women with adnexal masses. It also offers ASPiRA GenetiX, a genetic test for the risk of gynecologic cancer. In addition, the company operates Aspira Synergy, a testing platform and cloud service for decentralized access of protein biomarker and hereditary genetic testing; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. Further, its pipeline products include OVAWatch, EndoCheck, and OVAInherit. The company serves physicians, physician office laboratories, and national and regional laboratories. It has a collaborative research agreement with Baylor Genetics; an agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is headquartered in Austin, Texas.
Visit WebsiteEarnings History & Surprises
AWHEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | — | $-0.13 | — | — |
Q3 2025 | Aug 11, 2025 | — | $-0.07 | — | — |
Q2 2025 | May 13, 2025 | $-0.15 | $-8.58 | -5621.6% | ✗ MISS |
Q1 2025 | Mar 27, 2025 | $-0.15 | $-0.08 | +46.7% | ✓ BEAT |
Q4 2024 | Nov 19, 2024 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.32 | $-0.28 | +12.5% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.36 | $-0.39 | -8.3% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-0.39 | $-0.30 | +23.1% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.43 | $-0.48 | -11.6% | ✗ MISS |
Q3 2023 | Aug 14, 2023 | $-0.47 | $-0.28 | +40.4% | ✓ BEAT |
Q2 2023 | May 11, 2023 | $-0.75 | $-10.94 | -1358.7% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-0.90 | $-0.60 | +33.3% | ✓ BEAT |
Q4 2022 | Nov 10, 2022 | $-1.05 | $-0.60 | +42.9% | ✓ BEAT |
Q3 2022 | Aug 10, 2022 | $-0.07 | $-1.05 | -1400.0% | ✗ MISS |
Q2 2022 | May 11, 2022 | $-1.20 | $-1.20 | 0.0% | = MET |
Q1 2022 | Mar 23, 2022 | $-1.35 | $-1.20 | +11.1% | ✓ BEAT |
Q4 2021 | Nov 10, 2021 | $-1.20 | $-1.35 | -12.5% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.90 | $-0.90 | 0.0% | = MET |
Q2 2021 | May 13, 2021 | $-3.60 | $-0.75 | +79.2% | ✓ BEAT |
Q1 2021 | Mar 25, 2021 | $-0.60 | $-8.70 | -1350.0% | ✗ MISS |
Frequently Asked Questions about AWH
What is AWH's current stock price?
What is the analyst price target for AWH?
What sector is Aspira Women's Health Inc. in?
What is AWH's market cap?
Does AWH pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to AWH for comparison